| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 158, Issue 7 3359-3365, Copyright © 1997 by American Association of Immunologists
ARTICLES |
K Tsung, JB Meko, GR Peplinski, YL Tsung and JA Norton
Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Although IL-12 possesses the most potent single-cytokine antitumor efficacy, the mechanism by which IL-12 exerts its antitumor activities remains unclear. Using a complete tumor regression model induced by IL- 12 treatment, we demonstrate that the antitumor response induced by IL- 12 is mediated by a Th1 cell-directed process, with the macrophage as the effector cell and nitric oxide produced by the activated macrophage as the effector molecule. The induction of the Th1 response by IL-12 depends on the existence of a host T cell response to the tumor before IL-12 administration. IL-12 treatment causes the complete regression of 10-day established s.c. tumors (4-8 mm). Associated with the induction of tumor necrosis, activated macrophages expressing high levels of inducible nitric oxide synthase were found surrounding the tumor. The importance of nitric oxide as the effector molecule was further confirmed by the delay and loss of tumor regression in the presence of a nitric oxide synthase inhibitor in vivo. Examination of tumor- associated T cells indicates that IL-12 induces production of the Th1 cytokine IFN-gamma and suppresses production of IL-2, IL-4, and IL-10 at the tumor site, where these are found to be the predominant cytokines produced by tumor-associated T cells before IL-12 treatment. These findings demonstrate that IL-12 plays an essential role in the induction of an effective Th1 type of cell-mediated immune response against established tumors.
This article has been cited by other articles:
|
|
 |
|
  H. Li, W. Wojciechowski, C. Dell'Agnola, N. E. Lopez, and I. Espinoza-Delgado IFN-{gamma} and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways J. Immunol., September 15, 2006; 177(6): 3554 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oniki, H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res., June 15, 2006; 66(12): 6395 - 6404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Helguera, J. A. Rodriguez, and M. L. Penichet Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Norton, M. Li, N. C. Lee, and K. Tsung Inhibition of Host Signal Transducer and Activator of Transcription Factor 6 Results in Cure With Cyclophosphamide and Interleukin 12 Immunotherapy Ann. Surg. Oncol., January 1, 2006; 13(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion Cancer Res., December 15, 2004; 64(24): 9124 - 9130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Chin, C. H.T. Miller, L. Graham, M. Parviz, S. Zacur, B. Patel, A. Duong, and H. D. Bear Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes Int. Immunol., September 1, 2004; 16(9): 1283 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Mandpe, K. Tsung, and J. A. Norton Cure of an Established Nonimmunogenic Tumor, SCC VII, With a Novel Interleukin 12-Based Immunotherapy Regimen in C3H Mice Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma} J. Immunol., January 1, 2003; 170(1): 400 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tseng, B. Levin, T. Hirano, H. Yee, C. Pampeno, and D. Meruelo In Vivo Antitumor Activity of Sindbis Viral Vectors J Natl Cancer Inst, December 4, 2002; 94(23): 1790 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsung, J. P. Dolan, Y. L. Tsung, and J. A. Norton Macrophages as Effector Cells in Interleukin 12-induced T Cell-dependent Tumor Rejection Cancer Res., September 1, 2002; 62(17): 5069 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Burdelya, R. Catlett-Falcone, A. Levitzki, F. Cheng, L. B. Mora, E. Sotomayor, D. Coppola, J. Sun, S. Sebti, W. S. Dalton, et al. Combination Therapy with AG-490 and Interleukin 12 Achieves Greater Antitumor Effects than Either Agent Alone Mol. Cancer Ther., September 1, 2002; 1(11): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Segal, N. C. Lee, Y. L. Tsung, J. A. Norton, and K. Tsung The Role of IFN-{gamma} in Rejection of Established Tumors by IL-12 : Source of Production and Target Cancer Res., August 15, 2002; 62(16): 4696 - 4703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Panjwani, L. Popova, and P. K. Srivastava Heat Shock Proteins gp96 and hsp70 Activate the Release of Nitric Oxide by APCs J. Immunol., March 15, 2002; 168(6): 2997 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Le, N. C. Lee, K. Tsung, and J. A. Norton Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12 J. Immunol., December 15, 2001; 167(12): 6765 - 6772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Karnbach, M. R. Daws, E. C. Niemi, and M. C. Nakamura Immune Rejection of a Large Sarcoma Following Cyclophosphamide and IL-12 Treatment Requires Both NK and NK T Cells and Is Associated with the Induction of a Novel NK T Cell Population J. Immunol., September 1, 2001; 167(5): 2569 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells Cancer Res., December 1, 2000; 60(23): 6696 - 6703. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Andrews, A. Ribas, L. H. Butterfield, C. M. Vollmer, F. C. Eilber, V. B. Dissette, S. D. Nelson, P. Shintaku, S. Mekhoubad, T. Nakayama, et al. Adenovirus-Interleukin-12-mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model Is Not Dependent on CD1-restricted Natural Killer T Cells Cancer Res., November 1, 2000; 60(22): 6457 - 6464. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Smyth, M. Taniguchi, and S. E. A. Street The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent J. Immunol., September 1, 2000; 165(5): 2665 - 2670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oshikawa, F. Shi, A. L. Rakhmilevich, P. M. Sondel, D. M. Mahvi, and N.-S. Yang Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA PNAS, November 9, 1999; 96(23): 13351 - 13356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L) J. Immunol., October 15, 1999; 163(8): 4462 - 4472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. W. S. Robinson, and B. Scott Cytokine Gene Therapy of Mesothelioma . Immune and Antitumor Effects of Transfected Interleukin-12 Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 347 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
M. Rodolfo, C. Zilocchi, P. Accornero, B. Cappetti, I. Arioli, and M. P. Colombo IL-4-Transduced Tumor Cell Vaccine Induces Immunoregulatory Type 2 CD8 T Lymphocytes That Cure Lung Metastases Upon Adoptive Transfer J. Immunol., August 15, 1999; 163(4): 1923 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zeidler, G. Reisbach, B. Wollenberg, S. Lang, S. Chaubal, B. Schmitt, and H. Lindhofer Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing J. Immunol., August 1, 1999; 163(3): 1246 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsui, J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and J. A. Berzofsky A Model for CD8+ CTL Tumor Immunosurveillance and Regulation of Tumor Escape by CD4 T Cells Through an Effect on Quality of CTL J. Immunol., July 1, 1999; 163(1): 184 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Peng, M. L. Penichet, and S. L. Morrison A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity J. Immunol., July 1, 1999; 163(1): 250 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer J. Immunol., January 1, 1999; 162(1): 609 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. Scott, and B. W. S. Robinson Interleukin-12 Induces an Effective Antitumor Response in Malignant Mesothelioma Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 738 - 746. [Abstract] [Full Text]
|
|
|
|
|
|
H.-M. Hu, W. J. Urba, and B. A. Fox Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile J. Immunol., September 15, 1998; 161(6): 3033 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus J. Immunol., June 1, 1998; 160(11): 5465 - 5474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsung, J. B. Meko, Y. L. Tsung, G. R. Peplinski, and J. A. Norton Immune Response Against Large Tumors Eradicated by Treatment with Cyclophosphamide and IL-12 J. Immunol., February 1, 1998; 160(3): 1369 - 1377. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
